Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daewoong Inks Autotelic Deal To Help International Expansion

This article was originally published in PharmAsia News

Executive Summary

After a fairly smooth launch for its combination drug Olostar in South Korea last year, Daewoong is now taking the product into global markets as part of its international expansion strategy.

You may also be interested in...



Merck Turns Again To Daewoong For Co-promotion In South Korea

SEOUL - Merck & Co. Inc. signed a co-promotion deal with Korea's Daewoong Pharmaceutical Co. Ltd. to sell Merck's Vytorin (ezetimibe/simvastatin) in Korea, adding to the companies' similar agreements for Fosamax (alendronate) and Januvia (sitagliptin), which have been sold in Korea since 2008

Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III

Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.

Dupixent Shines At ATS, But Experts Question Which Novel Biologic Physicians Will Choose

Phase III studies testing Dupixent in moderate-to-severe asthma were largely positive, but subgroup details raise questions about how it will compete against biologics targeting the IL-5 pathway. Some experts urge comparison trials to inform physicians' decisions about long-term use.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC088753

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel